NASDAQ: GYRE - Gyre Therapeutics, Inc.

छह महीने के लिए लाभप्रदता: +3.06%

पदोन्नति कार्यक्रम Gyre Therapeutics, Inc.


कंपनी के बारे में

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease.

अधिक जानकारी
The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

IPO date 2006-04-12
ISIN US4037831033
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Дивиденд ао 25.05
Сайт https://www.gyretx.com
Цена ао 16.79
प्रति दिन मूल्य परिवर्तन: -5.18% (13.13)
प्रति सप्ताह मूल्य परिवर्तन: +11.76% (11.14)
प्रति माह मूल्य परिवर्तन: +6.41% (11.7)
3 महीने में कीमत में बदलाव: -2.43% (12.76)
छह महीने में कीमत में बदलाव: +3.06% (12.08)
प्रति वर्ष मूल्य परिवर्तन: -51.54% (25.69)
3 वर्षों में मूल्य परिवर्तन: +516.34% (2.02)
5 वर्षों में मूल्य परिवर्तन: +12.36% (11.08)
10 वर्षों में मूल्य परिवर्तन: 0% (12.45)
वर्ष की शुरुआत से मूल्य परिवर्तन: +13.08% (11.01)

बहुत मूल्यवान समझना

नाम अर्थ श्रेणी
P/S 17.22 1
P/BV 140.07 1
P/E 0 0
EV/EBITDA 16.55 6
कुल: 2.13

क्षमता

नाम अर्थ श्रेणी
ROA, % -79.74 0
ROE, % 587.14 10
कुल: 5

लाभांश

नाम अर्थ श्रेणी
Div yield, % 0 0
DSI 0.5 5
कुल: 2.22

कर्तव्य

नाम अर्थ श्रेणी
Debt/EBITDA 0.0035 10
कुल: 10

विकास का आवेग

नाम अर्थ श्रेणी
लाभप्रदता Revenue, % 1890733.33 10
लाभप्रदता Ebitda, % -347.89 0
लाभप्रदता EPS, % 123.83 10
कुल: 6

संस्थानों आयतन शेयर करना, %
Renaissance Technologies, LLC 39379 0.1
Geode Capital Management, LLC 17250 0.05
Vanguard Group Inc 13793 0.04
Blackrock Inc. 10250 0.03
Citigroup Inc. 7748 0.02
Morgan Stanley 6516 0.02
Kynam Capital Management, LP 6004 0.02
Northern Trust Corporation 5761 0.02
State Street Corporation 4840 0.01
Nantahala Capital Management, LLC 4520 0.01

ETF शेयर करना, % वर्ष के लिए लाभप्रदता, % लाभांश, %
iShares Morningstar Small Cap Value ETF 0.00477 26.7 2.50476
iShares Morningstar Small-Cap Value ETF 0.00477 201.65 2.50476
iShares Morningstar Small-Cap ETF 0.00416 30.1 1.60498
iShares Morningstar Small-Cap ETF 0.00416 391.25 1.60498
iShares Morningstar Small-Cap Growth ETF 0.00411 33.63 0.72598
iShares Morningstar Small-Cap Growth ETF 0.00411 587.89 0.72598

पर्यवेक्षक नौकरी का शीर्षक भुगतान जन्म का साल
Dr. Han Ying Ph.D. CEO & Director 10.5k 1966 (59 साल)
Mr. Songjiang Ma President & Director N/A 1956 (69 साल)
Ms. Ruoyu Chen Chief Financial Officer 121.35k 1971 (54 वर्ष)
Mr. Weiguo Ye Chief Operating Officer 274.62k 1978 (47 साल)
Ms. Seline E. Miller CPA Senior Vice President of Finance N/A 1970 (55 साल)

पता: United States, San Diego. CA, 12770 High Bluff Drive - Google मानचित्र में खोलें, यांडेक्स मानचित्र खोलें
वेबसाइट: https://www.gyretx.com